Academic Journal
Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer
| العنوان: | Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer |
|---|---|
| المؤلفون: | Shuta Ohara, Kenichi Suda, Akira Hamada, Masato Chiba, Masaoki Ito, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani |
| المصدر: | Thoracic Cancer, Vol 15, Iss 31, Pp 2229-2234 (2024) |
| بيانات النشر: | Wiley, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | non‐small cell lung cancer, plasma fibrinogen, programmed cell death ligand 1, SUVmax, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract Background Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1) expression. However, it is not always possible to obtain sufficient tumor specimens for biomarker testing before surgery. In this study, we explored clinical factors that can predict high PD‐L1 expression. Methods We retrospectively enrolled 340 lung cancer patients who received pulmonary resection between 2014 and 2023 and who had PD‐L1 expression data. Chi‐squared tests and logistic regression analyses were used to identify clinical factors associated with high PD‐L1 status. Results Univariable and multivariable analyses revealed that smoking, high maximum standardized uptake value (SUVmax) of 18F‐fluorodeoxyglucose positron emission computed tomography (18F‐FDG PET/CT), and high plasma fibrinogen are independent predictors of high PD‐L1 expression. A predictive score for high PD‐L1 expression (ranging from 0 to 3) was developed based on these parameters. Notably, only 5% of patients with a score of 0 exhibited high PD‐L1 expression, whereas this proportion increased to 53% for patients with a score of 3. Conclusion These results showed that plasma fibrinogen, smoking history, and SUVmax are predictors of high PD‐L1 expression, providing a basis for identifying patients expected to benefit from neoadjuvant ICI treatment. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1759-7714 1759-7706 |
| Relation: | https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714 |
| DOI: | 10.1111/1759-7714.15453 |
| URL الوصول: | https://doaj.org/article/01fa212b64f949ff8f69a1fbe25e8ccd |
| رقم الانضمام: | edsdoj.01fa212b64f949ff8f69a1fbe25e8ccd |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.01fa212b64f949ff8f69a1fbe25e8ccd 1063 3 Academic Journal academicJournal 1063.02990722656 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.01fa212b64f949ff8f69a1fbe25e8ccd&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/01fa212b64f949ff8f69a1fbe25e8ccd [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=17597714&ISBN=&volume=15&issue=31&date=20241101&spage=2229&pages=2229-2234&title=Thoracic Cancer&atitle=Clinical%20factors%20associated%20with%20high%20PD%E2%80%90L1%20expression%20in%20patients%20with%20early%E2%80%90stage%20non%E2%80%90small%20cell%20lung%20cancer&id=DOI:10.1111/1759-7714.15453 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Shuta+Ohara%22">Shuta Ohara</searchLink><br /><searchLink fieldCode="AR" term="%22Kenichi+Suda%22">Kenichi Suda</searchLink><br /><searchLink fieldCode="AR" term="%22Akira+Hamada%22">Akira Hamada</searchLink><br /><searchLink fieldCode="AR" term="%22Masato+Chiba%22">Masato Chiba</searchLink><br /><searchLink fieldCode="AR" term="%22Masaoki+Ito%22">Masaoki Ito</searchLink><br /><searchLink fieldCode="AR" term="%22Masaki+Shimoji%22">Masaki Shimoji</searchLink><br /><searchLink fieldCode="AR" term="%22Toshiki+Takemoto%22">Toshiki Takemoto</searchLink><br /><searchLink fieldCode="AR" term="%22Junichi+Soh%22">Junichi Soh</searchLink><br /><searchLink fieldCode="AR" term="%22Yasuhiro+Tsutani%22">Yasuhiro Tsutani</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Thoracic Cancer, Vol 15, Iss 31, Pp 2229-2234 (2024) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Wiley, 2024. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2024 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22non‐small+cell+lung+cancer%22">non‐small cell lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22plasma+fibrinogen%22">plasma fibrinogen</searchLink><br /><searchLink fieldCode="DE" term="%22programmed+cell+death+ligand+1%22">programmed cell death ligand 1</searchLink><br /><searchLink fieldCode="DE" term="%22SUVmax%22">SUVmax</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Abstract Background Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1) expression. However, it is not always possible to obtain sufficient tumor specimens for biomarker testing before surgery. In this study, we explored clinical factors that can predict high PD‐L1 expression. Methods We retrospectively enrolled 340 lung cancer patients who received pulmonary resection between 2014 and 2023 and who had PD‐L1 expression data. Chi‐squared tests and logistic regression analyses were used to identify clinical factors associated with high PD‐L1 status. Results Univariable and multivariable analyses revealed that smoking, high maximum standardized uptake value (SUVmax) of 18F‐fluorodeoxyglucose positron emission computed tomography (18F‐FDG PET/CT), and high plasma fibrinogen are independent predictors of high PD‐L1 expression. A predictive score for high PD‐L1 expression (ranging from 0 to 3) was developed based on these parameters. Notably, only 5% of patients with a score of 0 exhibited high PD‐L1 expression, whereas this proportion increased to 53% for patients with a score of 3. Conclusion These results showed that plasma fibrinogen, smoking history, and SUVmax are predictors of high PD‐L1 expression, providing a basis for identifying patients expected to benefit from neoadjuvant ICI treatment. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1759-7714<br />1759-7706 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1111/1759-7714.15453 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/01fa212b64f949ff8f69a1fbe25e8ccd" linkWindow="_blank">https://doaj.org/article/01fa212b64f949ff8f69a1fbe25e8ccd</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.01fa212b64f949ff8f69a1fbe25e8ccd ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1111/1759-7714.15453
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 6
[StartPage] => 2229
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => non‐small cell lung cancer
[Type] => general
)
[1] => Array
(
[SubjectFull] => plasma fibrinogen
[Type] => general
)
[2] => Array
(
[SubjectFull] => programmed cell death ligand 1
[Type] => general
)
[3] => Array
(
[SubjectFull] => SUVmax
[Type] => general
)
[4] => Array
(
[SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens
[Type] => general
)
[5] => Array
(
[SubjectFull] => RC254-282
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shuta Ohara
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kenichi Suda
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Akira Hamada
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Masato Chiba
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Masaoki Ito
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Masaki Shimoji
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Toshiki Takemoto
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Junichi Soh
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yasuhiro Tsutani
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 11
[Type] => published
[Y] => 2024
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 17597714
)
[1] => Array
(
[Type] => issn-print
[Value] => 17597706
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 15
)
[1] => Array
(
[Type] => issue
[Value] => 31
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Thoracic Cancer
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |